{"schema_version":"secwatch.filing_event.v1","accession":"0001517022-24-000029","form_type":"8-K","ticker":"AKBA","cik":"0001517022","company_name":"Akebia Therapeutics, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.461255+00:00","generated_at":"2026-06-04T19:22:03.992461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akebia reports Q4 2023 net income $0.6M, Auryxia $53.2M; vadadustat PDUFA Mar 27","bullets":["Net income of $0.6M in Q4 2023 vs net loss $6.1M a year ago; full-year net income $51.9M vs loss $94.2M in 2022.","Auryxia net product revenue $53.2M in Q4, $170.3M full year, within guidance of $170-175M.","Vadadustat PDUFA date March 27, 2024; Akebia preparing for potential U.S. launch.","Closed $55M BlackRock term loan and raised $26M via ATM; cash $42.9M at year-end, sufficient for 24 months if vadadustat approved.","Appointed Nicholas Grund as Chief Commercial Officer; introduced early-stage pipeline programs AKB-9090 and AKB-10108."],"urls":{"canonical":"https://secwatch.observer/filing/0001517022-24-000029","json":"https://secwatch.observer/filing/0001517022-24-000029.json","markdown":"https://secwatch.observer/filing/0001517022-24-000029.md","text":"https://secwatch.observer/filing/0001517022-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/akba-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:22:03.992461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6228e1cc1c79a5afe8f0289c159377f1ef74087d","claim":"Akebia Therapeutics, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $56.2 million, net income $0.6 million.","evidence_excerpt":"Financial Results • Revenues: Total revenues were $56.2 million for the fourth quarter of 2023 compared to $55.8 million for the fourth quarter of 2022, and $194.6 million for the full-year 2023 compared to $292.5 million for the full-year 2022. ◦ Net product revenues were $53.2 million for the fourth quarter of 2023 compared to $50.3 million for the fourth quarter of 2022, and $170.3 million for the full-year 2023 compared to $176.9 million for the full-year 2022. ◦ License, collaboration and other revenues were $3.0 million for the fourth quarter of 2023 compared to $5.5 million for the fourth quarter of 2022, and $24.3 million for the full-year 2023 compared to $115.5 million for the full-year 2022. • COGS: Cost of goods sold was $18.7 million for the fourth quarter of 2023 compared to a benefit of $3.4 million for the fourth quarter of 2022, and $74.1 million for the full-year 2023 compared to $85.6 million for the full-year 2022. Akebia continues to record a non-cash intangible am","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$56.2 million"},{"label":"Net income","value":"$0.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e66819502f1f8a9e01473daf2c61fbd4a177787f","claim":"Akebia Therapeutics, Inc. reported the fiscal year ended December 31, 2023 results: revenue $194.6 million, net income $51.9 million.","evidence_excerpt":"Financial Results • Revenues: Total revenues were $56.2 million for the fourth quarter of 2023 compared to $55.8 million for the fourth quarter of 2022, and $194.6 million for the full-year 2023 compared to $292.5 million for the full-year 2022. ◦ Net product revenues were $53.2 million for the fourth quarter of 2023 compared to $50.3 million for the fourth quarter of 2022, and $170.3 million for the full-year 2023 compared to $176.9 million for the full-year 2022. ◦ License, collaboration and other revenues were $3.0 million for the fourth quarter of 2023 compared to $5.5 million for the fourth quarter of 2022, and $24.3 million for the full-year 2023 compared to $115.5 million for the full-year 2022. • COGS: Cost of goods sold was $18.7 million for the fourth quarter of 2023 compared to a benefit of $3.4 million for the fourth quarter of 2022, and $74.1 million for the full-year 2023 compared to $85.6 million for the full-year 2022. Akebia continues to record a non-cash intangible am","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1517022/000151702224000029/0001517022-24-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Revenue","value":"$194.6 million"},{"label":"Net income","value":"$51.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}